Statements (62)
Predicate | Object |
---|---|
gptkbp:instance_of |
gptkb:Company
|
gptkbp:appointed_by |
injection
|
gptkbp:approves |
gptkb:FDA
|
gptkbp:are |
oral medications
cures for diabetes |
gptkbp:benefits |
gptkb:regular_insulin
|
gptkbp:can_be_used_with |
gptkb:product
lifestyle changes continuous glucose monitors oral hypoglycemics |
gptkbp:caused_by |
allergic reactions
|
gptkbp:developed_by |
gptkb:Company
pharmaceutical companies late 20th century |
gptkbp:has_impact_on |
blood glucose levels
|
gptkbp:has_variants |
peak times
duration of action onset times |
https://www.w3.org/2000/01/rdf-schema#label |
insulin analogs
|
gptkbp:improves |
glycemic control
|
gptkbp:includes |
gptkb:insulin_lispro
gptkb:insulin_aspart gptkb:insulin_degludec gptkb:insulin_detemir gptkb:insulin_glulisine |
gptkbp:influence |
insulin sensitivity
|
gptkbp:is_available_in |
gptkb:tablet
gptkb:railway_station various formulations vial various strengths |
gptkbp:is_compared_to |
gptkb:regular_insulin
|
gptkbp:is_considered |
essential medicines
modern treatment options |
gptkbp:is_evaluated_by |
clinical trials
efficacy and safety |
gptkbp:is_implemented_in |
hospital settings
|
gptkbp:is_monitored_by |
blood sugar levels
|
gptkbp:is_part_of |
insulin therapy
personalized medicine approaches diabetes care plans |
gptkbp:is_subject_to |
gptkb:municipality
regulatory approval insurance coverage |
gptkbp:is_used_by |
diabetes patients
|
gptkbp:is_used_for |
diabetes management
intensive insulin therapy manage postprandial glucose spikes prevent ketoacidosis |
gptkbp:is_used_in |
gestational diabetes
|
gptkbp:is_used_to |
achieve target A1 C levels
|
gptkbp:recommendation |
gptkb:hospital
|
gptkbp:requires |
prescription
|
gptkbp:risk_factor |
diabetes complications
|
gptkbp:side_effect |
weight gain
hypoglycemia |
gptkbp:storage |
room temperature
|
gptkbp:type |
synthetic insulin
|
gptkbp:used_in |
type 2 diabetes
type 1 diabetes |
gptkbp:bfsParent |
gptkb:Humalog
|
gptkbp:bfsLayer |
4
|